In a nutshell This study compared the safety and effectiveness of semaglutide (Ozempic) and canagliflozin (Invokana) for patients with uncontrolled type 2 diabetes (T2D). The authors found that semaglutide more effectively reduced blood glucose levels and body weight than canagliflozin. Some background Often, patients with T2D are given...Read More
Diabetes medication(s)-Non-insulin injected drugs Posts on Medivizor
Do glucagon-like peptide-1 receptor agonist drugs reduce heart disease and stroke in patients with diabetes?
In a nutshell This study examined if glucagon-like peptide-1 receptor agonist (GLP-1RA) drugs could reduce the rate of heart disease and stroke in patients with Type 2 diabetes (T2D). The authors found that fewer patients who received GLP-1RA drugs developed heart disease or stroke compared to those who received a placebo. Some background...Read More
Is IDegLira more effective than degludec or liraglutide alone for treating uncontrolled Type 2 diabetes?
In a nutshell This study compared IDegLira (Xultophy) to insulin degludec (Tresiba) or liraglutide (Victoza) alone in patients with uncontrolled Type 2 diabetes (T2D). The authors concluded that combined IDegLira was more effective and had fewer side effects than either insulin medication alone. Some background One of the main...Read More
In a nutshell This study compared the effectiveness and safety of a combination of insulin glargine (Lantus) and lixisenatide (Lyxumia), called iGlarLixi, to either drug on its own, in people with type 2 diabetes (T2D). It was determined that iGlarLixi was more effective in reducing HbA1c, and did not increase the risk of side effects. Some background...Read More
In a nutshell This study investigated the suitability of IDegLira for treating patients with uncontrolled type 2 diabetes. The authors concluded that using IDegLira was safe and effective at reducing blood-sugar levels. Some background IDegLira is an injectable, fixed-ratio combination of basal insulin (degludec) and a glucagon-like peptide-1...Read More
In a nutshell This study compared the effectiveness of the three long-acting GLP-1RAs: once-weekly exenatide (Byetta), dulaglutide (Trulicity), and albiglutide (Tanzeum). The authors concluded that after six months all three treatments equally reduced HbA1c. Some background Glucagon-like peptide-1 receptor agonists...Read More
Does autoinjected exenatide suspension improve blood glucose control in patients with type 2 diabetes on metformin therapy?
In a nutshell This study assessed the safety and effectiveness of a new formulation of exenatide compared to sitaglipitin in patients with sub-optimal blood sugar control taking metformin. This study concluded that exenatide reduced blood sugar levels over 3 months more effectively than sitaglipitin. Some background There are many blood...Read More
In a nutshell This study examined the effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on death, heart attacks, stroke, and heart failure in people with type 2 diabetes (T2D). They determined that GLP-1 RAs were associated with a reduced risk of heart attacks and death from cardiovascular causes. Some background Glucagon-like...Read More
In a nutshell This study investigated whether type 2 diabetes patients were at increased risk of weight gain when starting insulin treatment. Weight gain differed depending on the patient’s weight when starting insulin treatment. Some background Type 2 diabetes is a progressive disease where the cells in the pancreas that produce insulin,...Read More
In a nutshell This study investigated whether type 2 diabetes patients were at increased risk of kidney damage if their blood pressure surged during hypoglycemic (dangerously low levels of glucose) events. The study concluded that kidney function did worsen in patients whose blood pressure surged during severe hypoglycemic events. Some...Read More
In a nutshell This early-phase trial examined whether aleglitazar could be of benefit for the treatment of type 2 diabetes. The authors concluded that aleglitazar improves both blood glucose and cholesterol levels among diabetic patients. As of 2013, all further drug development of aleglitazar was halted...Read More